ArticleMicrobial cell factories2022
Metabolic engineering of Escherichia coli for efficient production of L-5-hydroxytryptophan from glucose.
Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Systems metabolic engineering of a plasmid-freeSynthetic and systems biotechnology · 2027Article
- Genome-integrated engineering ofSynthetic and systems biotechnology · 2027Article
- Engineering a heme-dependent tryptophan hydroxylase pathway inSynthetic and systems biotechnology · 2026Article
- Application and progress of synthetic biology technology in amino acid production.Bioprocess and biosystems engineering · 2026Review
- Recent advances in nonprotein amino acids: insights from function to biosynthesis.Journal of animal science and biotechnology · 2026Review
- Co-utilization of glucose and xylose in synthetic Escherichia coli consortia for efficient 2-hydroxy-3-methylvalerate biosynthesis.Biotechnology for biofuels and bioproducts · 2025Article
- Combination strategies of gut microbiota in cancer therapy through metabolic reprogramming and immune remodeling.Cell communication and signaling : CCS · 2025Review
- CRISPR-Cas9-based one-step multiplexed genome editing through optimizing guide RNA processing strategies inSynthetic and systems biotechnology · 2025Article
- Engineered phenylalanine hydroxylase coupled with an effective cofactor synthesis and regeneration system for high-yield production of 5-hydroxytryptophan.Bioresources and bioprocessing · 2025Article
- Production of aromatic amino acids and their derivatives by Escherichia coli and Corynebacterium glutamicum.World journal of microbiology & biotechnology · 2025Review
- Modulation of Aromatic Amino Acid Metabolism by Indigenous Non-Foods (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
background5-hydroxytryptophan (5-HTP), the direct biosynthetic precursor of the neurotransmitter 5-hydroxytryptamine, has been shown to have unique efficacy in the treatment of a variety of disorders, including depression, insomnia, and chronic headaches, and is one of the most commercially valuable amino acid derivatives. However, microbial fermentation for 5-HTP production continues to face many challenges, including low titer/yield and the presence of the intermediate L-tryptophan (L-Trp), owing to the complexity and low activity of heterologous expression in prokaryotes. Therefore, there is a need to construct an efficient microbial cell factory for 5-HTP production.
resultsWe describe the systematic modular engineering of wild-type Escherichia coli for the efficient fermentation of 5-HTP from glucose. First, a xylose-induced T7 RNA polymerase-P
conclusionIn this study, we demonstrate the successful design of a cell factory for high-level 5-HTP production, combined with simple processes that have potential for use in industrial applications in the future. Thus, this study provides a reference for the production of high-value amino acid derivatives using a systematic modular engineering strategy and a basis for an efficient engineered strain development of 5-HTP high-value derivatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.